https://www.selleckchem.com/pe....ptide/tirzepatide-ly
0 versus 60.84, respectively. Additionally, the median months disease-free survival was lower in cases with genetic alterations in the OXTR gene as compared to cases without alterations (8.64 versus 21.55, respectively). OXTR is a promising prognostic biomarker for HCC, and OXTR antagonists could have a future role as therapeutic agents for a subset of HCC patients. Further study of the detailed molecular mechanisms of OXT and OXTR in HCC is warranted. OXTR is a promising prognostic biomarker for HCC, and OXTR antagonists c
Curtir
Comentario
Compartilhar
